The action of extracellular NAD+ on gluconeogenesis in the perfused rat liver.
In the rat liver NAD+ infusion produces increases in portal perfusion pressure and glycogenolysis and transient inhibition of oxygen consumption. The aim of the present work was to investigate the possible action of this agent on gluconeogenesis using lactate as a gluconeogenic precursor. Hemoglobin-free rat liver perfusion in antegrade and retrograde modes was used with enzymatic determination of glucose production and polarographic assay of oxygen uptake. NAD+ infusion into the portal vein (antegrade perfusion) produced a concentration-dependent (25-100 microM) transient inhibition of oxygen uptake and gluconeogenesis. For both parameters inhibition was followed by stimulation. NAD+ infusion into the hepatic vein (retrograde perfusion) produced only transient stimulations. During Ca2+-free perfusion the action of NAD+ was restricted to small transient stimulations. Inhibitors of eicosanoid synthesis with different specificities (indo-methacin, nordihydroguaiaretic acid, bromophenacyl bromide) either inhibited or changed the action of NAD+. The action of NAD+ on gluconeogenesis is probably mediated by eicosanoids synthesized in non-parenchymal cells. As in the fed state, in the fasted condition extracellular NAD+ is also able to exert two opposite effects, inhibition and stimulation. Since inhibition did not manifest significantly in retrograde perfusion it is likely that the generating signal is located in pre-sinusoidal regions.
Martins
Adriana G
AG
Laboratory of Liver Metabolism, University of Maringá, 87020900 Maringá, Brazil.
Constantin
Jorgete
J
Bracht
Fabrício
F
Kelmer-Bracht
Ana Maria
AM
Bracht
Adelar
A
D000098:Acetophenones / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage / Q000494:pharmacology; D002118:Calcium / Q000008:administration & dosage / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D005943:Gluconeogenesis / Q000187:drug effects*; D005947:Glucose / Q000096:biosynthesis; D007213:Indomethacin / Q000008:administration & dosage / Q000494:pharmacology; D007260:Infusion Pumps; D019344:Lactic Acid / Q000008:administration & dosage / Q000494:pharmacology; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D009637:Masoprocol / Q000008:administration & dosage / Q000494:pharmacology; D015999:Multivariate Analysis; D009243:NAD / Q000008:administration & dosage / Q000494:pharmacology*; D010101:Oxygen Consumption / Q000187:drug effects; D010477:Perfusion / Q000379:methods; D010741:Phospholipases A / Q000037:antagonists & inhibitors; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors
D000098:Acetophenones; D000975:Antioxidants; D004791:Enzyme Inhibitors; D009243:NAD; D019344:Lactic Acid; D009637:Masoprocol; D010741:Phospholipases A; D005947:Glucose; C006821:4-bromophenacyl bromide; D002118:Calcium; D007213:Indomethacin